Nicotinic α4β2 receptor imaging agents
Authors:
- Balasubramaniam EaswaramoorthyBEBalasubramaniam Easwaramoorthy
- Daphne CollinsDCDaphne Collins
- Bradley T. ChristianBCBradley T. Christian
- Bingzhi ShiBSBingzhi Shi
- Tanjore K. NarayananTNTanjore K. Narayanan
- Steven G. PotkinSPSteven G. Potkin
- Jogeshwar MukherjeeJMJogeshwar Mukherjee
- 1 April 2006
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 33 (3) , 295-304
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Evaluation of 5-(2-(4-pyridinyl)vinyl)-6-chloro-3-(1-methyl-2-(S)-pyrrolidinylmethoxy)pyridine and its analogues as PET radioligands for imaging nicotinic acetylcholine receptorsJournal of Neurochemistry, 2004
- 6‐[18F]Fluoro‐A‐85380, a new PET tracer for the nicotinic acetylcholine receptor: Studies in the human brain and in vivo demonstration of specific binding in white matterSynapse, 2004
- 2 [ 18 F]F‐A85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humansThe FASEB Journal, 2003
- Localization of [3H]nicotine, [3H]cytisine, [3H]epibatidine, and [125I]α‐bungarotoxin binding sites in the brain of Macaca mulattaJournal of Comparative Neurology, 2003
- Graphical analysis of 2‐[18F]FA binding to nicotinic acetylcholine receptors in rhesus monkey brainSynapse, 2003
- Measuring nicotinic receptors with characteristics of α4β2, α3β2 and α3β4 subtypes in rat tissues by autoradiographyJournal of Neurochemistry, 2002
- Abnormal Regulation of High Affinity Nicotinic Receptors in Subjects with SchizophreniaNeuropsychopharmacology, 2000
- Synthesis and Nicotinic Acetylcholine Receptor in Vivo Binding Properties of 2-Fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: A New Positron Emission Tomography Ligand for Nicotinic ReceptorsJournal of Medicinal Chemistry, 1999
- Novel 3-Pyridyl Ethers with Subnanomolar Affinity for Central Neuronal Nicotinic Acetylcholine ReceptorsJournal of Medicinal Chemistry, 1996
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973